Personalized targeted glioblastoma therapies by ex vivo drug screening: Study protocol of the Advanced brain Tumor TheRApy Clinical Trial (ATTRACT).

Neurooncol Adv · 2025 · PMC12063086 · PMID 40351832

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a negative trendno p-value reported

The adaptive group sequential design allows for one interim analysis with stopping for futility in case a negative trend is observed and O’Brien & Fleming type boundaries to stop for efficacy.

also in 4,201 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.